Loading stock data…
$2.56+0.17 (+7.17%)
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States.
Atossa Therapeutics, Inc. in the Healthcare sector is trading at $2.56 with a market capitalization of $25M. Wall Street consensus targets $19.00 (3 analysts), implying a +642.2% move over the next 12 months. The stock is currently near its 52-week low of $1.70, remaining 42.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$8.69M↑ | -$9.87M↑ | -$11.44M↓ | -$9.25M↓ | -$9.04M |
| Net Income | -$8.49M↑ | -$9.59M↑ | -$10.94M↓ | -$8.69M↓ | -$8.42M |
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modula...